A BioNTech SE analyst advised investors to cash in on their profits from the US$30 billion ($40.15 billion) biotech’s recent advance, saying the German company now faces heightened competition from peers that are also developing vaccines.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply